

Date: 08/07/2020

To, BSE Limited P.J. Towers, Dalal Street, Mumbai – 400 001

Dear Sir/Madam,

Sub: Compliance with SEBI (Listing Obligations and Disclosure Regulations)
Regulations, 2015 (Quarter ended 30/06/2020)

With reference to the subject cited, please find attached the following:

Report on Corporate Governance	Reg. 15 (2) & 27(2) of SEBI (LODR) Regulations, 2015	
Reconciliation of Share Capital Audit Report	Capital Reg. 55A of SEBI (DP) Regulations, 1996/ Reg. 76 of SEBI (Depositories & Participants) Regulations, 2018	
Statement of Investor Grievance Redressal Mechanism	Reg. 13 (3) of SEBI (LODR) Regulations, 2015	

Request you take the same on records.

Thanking you.

For Trimurthi Limited

Arun Kumar Bhangadia

Managing Director

(DIN: 00021024)

Encl: as above

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.) 4-4-231/1/2/ABC, Inderbagh, Sultanbazar, Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370 Emall : Info@trimurthidrugs.com

Website: www.trimurthidrugs.com CIN No: L67120TG1994PLC018956



Date: 08/07/2020

To, BSE Limited P.J. Towers, Dalal Street, Mumbai – 400 001

Dear Sir/Madam,

Sub: Compliance with Regulation 15 (2) and 27(2) of SEBI (Listing Obligations and Disclosure Regulations) Regulations, 2015 - Corporate Governance Report (Quarter ended 30/06/2020)

Unit: Trimurthi Limited Scrip Code: 536565

With reference to the subject cited above relating to the Non - applicability of Report on Corporate Governance for the Quarter ended 30/06/2020, we hereby submit the following as on last day of Previous Audited Financial Year (31/03/2020):

Paid Up Capital of the Company = Rs. 8,10,00,000/- (81,00,000 Equity shares of Rs.10/- each)
Net worth = Rs. 12,07,09,968/-

Further, we hereby state that as per the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 notified on 2nd September, 2015, is **Not Applicable** to the Company since the Paid-up Capital of the Company is less than 10 Crores and the Net worth of the Company is less than 25 Crores as on the last day of previous audited financial year.

Request you take the same on records.

Thanking you.

For Trimurthi Limited

Arun Kumar Bhangadia

Managing Director

DIN: 00021024

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,

Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

Email: info@trimurthidrugs.com Website: www.trimurthidrugs.com CIN No: L67120TG1994PLC018956



To, The Secretary, The Bombay Stock Exchange Limited Floor 25, P.J. Towers, Dalal Street, Mumbai - 400 001

Dear Sir,

Sub: Quarterly compliance under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In terms of Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to submit the statement as detailed below with respect to Investor grievances pending at the beginning of the quarter, received, disposed and remaining unresolved at the end of the quarter 30/06/2020.

Statement of Investor Complaints for the Quarter ended 30-06-2020.

S.NO	Particulars	As on 30-06-2020
1	Pending at the beginning of the Quarter	NIL
2	Received during the Quarter	NIL
3	Disposed off during the Quarter	NIL
4	Remaining unresolved at the end of the Quarter	NIL

We request you to take the same on record and acknowledge.

Thanking you

For TRIMURTHI LIMITED

Arun Kumar Bhangadia

Managing Director

DIN: 00021024

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.) 4-4-231/1/2/ABC, Inderbagh, Sultanbazar,

Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

Email: info@trimurthidrugs.com Website: www.trimurthidrugs.com CIN No: L67120TG1994PLC018956



To,
The Secretary,
Listing Department
The Bombay Stock Exchange Limited
Floor 25, P.J. Towers,
Dalal Street,
Mumbai - 400 001

Sub: Compliance Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2020.

Dear Sir,

We are enclosing herewith the Certificate dated 02/07/2020 issued by Venture Capital and Corporate Investments Private Limited, Registrar and Share transfer Agent of the Company confirming compliance with Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter 30th June, 2020.

We request you to take the same on record and acknowledge.

Thanking you

For TRIMURTHI LIMITED

Arun Kumar Bhangadia

Managing Director

DIN: 00021024

Encl: As above

Copy to:

The Vice President
National Securities Depository Limited
Trade World, 'A' Wing, 4th Floor,
Kamala Mills Compound,
Senapati Bapat Marg, Lower Parel,
Mumbai-400013, MH, IN

The Vice President
Central Depository Services (India) Limited
Marathon Futures, A-Wing,
25th Floor, NM Joshi Marg, Lower Parel,
Mumbai-400013, MH, IN

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.) 4-4-231/1/2/ABC, Inderbagh, Sultanbazar, Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370 Email: info@trimurthidrugs.com

Website: www.trimurthidrugs.com CIN No: £67120TG1994PLC018956



Date: 08/07/2020

BSE Limited P.J. Towers, Dalal Street, Mumbai - 400 001

Sub: Trading Window Close Period

Unit: Trimurthi Limited Scrip Code: 536565

Dear Sir,

This is to inform that the Trading window closure period pursuant to Trimurthi Limited's code to Regulate, Monitor and Report Trading by Directors, Promoters, Designated employees and Specified connected persons of the Company will commence from today and end 48 hours after the financial results of the Company for the Quarter ending 30th June, 2020 become generally available.

This is for your information and records.

Thanking you. Yours faithfully,

For Trimurthi Limited

Arun Kumar Bhangadia

Managing Director

DIN: 00021024

Email: info@trimurthidrugs.com Website: www.frimurthidrugs.com CIN No: L67120TG1994PLC018956